Pfizer received official clearance in China to market Xianweiying (its GLP-1 agonist) for long-term weight management in adults classified as overweight or obese. The nod covers ongoing treatment to reduce body weight and manage obesity-related complications.

With China’s obesity market forecast to be worth several billion dollars over the next few years, Pfizer is now positioned to capture share alongside established and emerging GLP-1 therapies. Analysts expect pricing negotiations and distribution agreements to shape the product’s market penetration starting in mid-2026.

Xianweiying will face competition from other GLP-1 injectables and oral weight-loss candidates vying for rapid adoption. Success will depend on Pfizer’s marketing reach, physician education programs and patient access initiatives in Chinese provinces with the highest obesity prevalence.